Prestige Consumer Healthcare Inc. Completes Acquisition of LaCorium Health, Prices $400 Million Senior Notes Offering, and Announces First Quarter Fiscal 2027 Earnings Results Date

About this update from Prestige Consumer Healthcare Inc.

TARRYTOWN, N.Y., July 06, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) ("Prestige") today announced that it has closed the previously announced acquisition of LaCorium Health ("LaCorium"), priced a private offering of $400 million in senior notes, and will report its first quarter fiscal 2027 results on August 6, 2026. Completion of LaCorium Health Acquisition The Company completed the acquisition on July 1, 2026. The closing was finalized pursuant to the terms of the definitive agreement announced on May 13, 2026, under which Prestige agreed to acquire LaCorium for approximately $150 million in cash. The Company financed the transaction with cash on hand and existing credit facilities. Founded in Australia and introduced in 1998, LaCorium is a leader in Australian therapeutic skin care designed to treat individual skin ailments. Products are sold under the Dermal Therapy®, Flexitol®, and Crampeze® brands in need-state categories such as lip care (cold sores), skin care (eczema & acne), foot care (heel balm, antifungal), hair & scalp (eczema), and more. Approximately 75% of LaCorium's sales are generated in Australia, where the brand holds the #1 market position in lip care and the #3 position in foot care. LaCorium generates approximately $40 million in revenue annually and is expected to generate approximately $12 million in EBITDA, including the benefits from anticipated synergies, once the business is fully integrated. The Company expects LaCorium to deliver strong long-term revenue growth, supported by category growth, innovation, and continued geographic expansion.   Pricing of Senior Notes Offering Prestige has also priced an offering of $400 million in aggregate principal amount of 6.25% senior notes due 2034 (the "notes") in a private offering. The sale of the notes is expected to be completed on or about July 15, 2026, subject to customary closing conditions. The notes will be senior unsecured obligations of Prestige Brands, Inc. and will be guaranteed by the Company and certain of its domestic subsidiaries. The Company intends to use the net proceeds from the offering, together with cash on hand, to redeem all $400 million of Prestige's' outstanding 5.125% Senior Notes due January 2028, and to pay related fees and expenses. The change in interest expense is contemplated in Prestige's medium-term outloo...

View stock analysis, news, and events for Prestige Consumer Healthcare Inc.